Amplitude Surgical SAS

Ahmedabad: Indian pharma major Zydus Lifesciences Q4 FY24-25 revenue from operations went up 18 per cent year-on-year (YoY) to ₹6,527 crore. During the period the company reported a net profit of ₹1,170 crore, reflecting a marginal decline of 1 per cent against the year ago quarter while against the preceding quarter the net profit reflects an uptick of 14.4 per cent. EBITDA margin improved by 310 basis points on YoY basis to 32.6 per cent and total earnings stood at ₹2,125 crore, up against ₹1,630 crore reported in the corresponding period. The marginal dip in profit is attributed with a sharp contraction in revenue from the API business which reported a decline of 10.2 per cent to ₹123 crore, against the corresponding quarter revenue of ₹143 crore. “We made meaningful progress in our differentiated pipeline and added new capabilities to ensure sustainable growth and the commercial success of our extensive product portfolio combined with operating leverage has significantly bolstered financial health,” said Dr Sharvil Patel, Managing Director, Zydus Lifesciences. For the full financial year the company’s revenue from operations went up 18.9 per cent YoY to ₹23,241 crore, while the net profit increased by 17.3 per cent to ₹4,525 crore. The growth in revenue is attributed with the strong performance in US market— accounts for nearly 50 per cent if its total revenue.--- reported an uptick of 27.2 per cent to ₹11,050 crore and the Q4 revenue stood at ₹3,130 crore, up by 24.1 per cent on YoY basis. “US formulations business continued its upward journey with a robust growth driven by volume expansion and new product launches,” the company’s investor presentation reads. During Q4 the Indian drugmaker launched 5 new products in the US and received approval for 6 new products from the FDA. “Looking forward we will continue our execution success and deepening strategic partnerships to drive long term growth,” Dr Patel, noted. In the ongoing fiscal the company has also expanded its medical device portfolio with the acquisition of France-based Orthopedics device maker Amplitude Surgical for up to €300 million (around $326 million) More recently, the company obtained commercial rights of an aortic valve device from Brazil-based Braile Biomedica for Europe, India, and other select markets. By Online Bureau ,

Ahmedabad: Indian pharma major Zydus Lifesciences Q4 FY24-25 revenue from operations went up 18 per cent year-on-year (YoY) to ₹6,527 crore. During the period the company reported a net profit of ₹1,170 crore, reflecting a marginal decline of 1 per cent against the year ago quarter while against the preceding quarter the net profit reflects an uptick of 14.4 per cent. EBITDA margin improved by 310 basis points on YoY basis to 32.6 per cent and total earnings stood at ₹2,125 crore, up against ₹1,630 crore reported in the corresponding period. The marginal dip in profit is attributed with a sharp contraction in revenue from the API business which reported a decline of 10.2 per cent to ₹123 crore, against the corresponding quarter revenue of ₹143 crore. “We made meaningful progress in our differentiated pipeline and added new capabilities to ensure sustainable growth and the commercial success of our extensive product portfolio combined with operating leverage has significantly bolstered financial health,” said Dr Sharvil Patel, Managing Director, Zydus Lifesciences. For the full financial year the company’s revenue from operations went up 18.9 per cent YoY to ₹23,241 crore, while the net profit increased by 17.3 per cent to ₹4,525 crore. The growth in revenue is attributed with the strong performance in US market— accounts for nearly 50 per cent if its total revenue.--- reported an uptick of 27.2 per cent to ₹11,050 crore and the Q4 revenue stood at ₹3,130 crore, up by 24.1 per cent on YoY basis. “US formulations business continued its upward journey with a robust growth driven by volume expansion and new product launches,” the company’s investor presentation reads. During Q4 the Indian drugmaker launched 5 new products in the US and received approval for 6 new products from the FDA. “Looking forward we will continue our execution success and deepening strategic partnerships to drive long term growth,” Dr Patel, noted. In the ongoing fiscal the company has also expanded its medical device portfolio with the acquisition of France-based Orthopedics device maker Amplitude Surgical for up to €300 million (around $326 million) More recently, the company obtained commercial rights of an aortic valve device from Brazil-based Braile Biomedica for Europe, India, and other select markets. By Online Bureau ,

Zydus Lifesciences Ltd. on Tuesday, March 11, said its board of directors approved the acquisition of 85.6% equity shares of Amplitude Surgical SA, France. In an exchange filing, the company said the board approved entering into a put option agreement, share purchase agreements and other agreements to acquire, directly or through its affiliates, a controlling stake in the company from the existing shareholders at €6.25 per equity share. The same aggregates to a consideration value of €256.8 million. Subject to closing of the block acquisition of 85.6% equity shares, a mandatory simplified cash tender offer for all the remaining shares in the Target Entity or Amplitude Surgical SA, France, at the same purchase price of €6.25 per share of the latter. If the conditions are met at the end of the tender offer, the company will proceed with a compulsory acquisition of the remaining shares — 14.4% shares for €43.2 million — from the minority shareholders and delist the target entity, it added. The equity shares of Amplitude Surgical are listed on Euronext Paris. The total consideration for the entire 100% equity share capital would work out to €300 million. Zydus Life will acquire 85.6% of the equity shares of the target entity by acquiring 100% shares of the investment companies -- Auroralux SAS, Ampliman 1 SAS and Ampliman 2 SAS -- from PAI Partners and the management as well as by acquiring shares of the target entity held by two minority shareholders. "The proposed acquisition shall act as a platform to execute our global MedTech strategy and a natural existence for Zydus having a proven track record in the sciences and wellness segment. The block acquisition would be completed, and the mandatory simplified cash tender offer would be filed with Autorite des Marches Financiers (AMF) after the regulatory approvals are obtained, by the first half of the 2025 calendar year. The opening of the subsequent tender offer will then remain subject to AMF's clearance decision, Zydus Life said. Zydus Life shares were up 0.82% at ₹901 apiece at 2.40 pm on Tuesday, March 11. The stock has gained over 19% in the last six months.